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It has been recognized for centuries that
arsenic exposure can cause acute toxicity,
including death. Its propensity to cause
chronic toxicity and cancer via environmen-
tal exposure at low doses has now become
apparent. Arsenic has a long history of use as
an intentional poison, in medicines and pes-
ticides, and it is still found in folk medicines
and pesticides in many countries. Until other
therapies became available (in the late
1940s), syphilis and psoriasis were often
treated with arsenicals.
Interest in environmental arsenic has dra-
matically increased in recent years. This stems
from the pollution of drinking water and
other environmental media in geographic
areas. Millions now suffer from the effects of
chronic arseniasis, which represents a major
international public health dilemma. The
potential for cancer is a very major concern.
The U.S. National Research Council has
recently concluded, based on epidemiologic
studies, that the evidence is now sufﬁcient to
include lung and bladder cancer, along with
the skin cancers, as being caused by ingestion
of inorganic arsenic (1). They further con-
cluded that there is some indication that
arsenic may induce cancers in other organs,
although the evidence is not as strong.
Chronic arsenic exposure has been impli-
cated in several noncancerous conditions, in
particular, skin disease, diabetes mellitus,
hypertension and cardiovascular disease, per-
turbed porphyrin metabolism, and irre-
versible noncirrhotic portal hypertension (1).
It has been long known that arsenic exposure
is associated with skin pathology, including
hyperpigmentation, hyperkeratosis, and skin
cancers. In the majority of cases in which an
internal cancer has been ascribed to arsenic
exposure, a dermatologic hallmark of arsenic
poisoning was also identiﬁed (2).
Effects of arsenic on the liver have been
suggested in a few case reports, although the
pathology has not been well described. In
addition to noncirrhotic portal hypertension
(3), other liver pathology has been described,
including hepatic enlargement, hepatocellu-
lar carcinoma (4), and liver angiosarcoma
(5). Epidemiologic studies have not con-
ﬁrmed the association between arsenic expo-
sure and hepatocellular carcinoma and liver
angiosarcomas. In this article we present two
cases of liver cancer that appear to be associ-
ated with arsenic exposure, one involving a
hepatocellular carcinoma and the other a
liver angiosarcoma.
Materials and Methods
One impediment to better treatment and
prevention of chronic arsenic–induced toxicity
and cancer is the rudimentary knowledge of
the responsible biological mechanisms. Further,
the exact nature of the carcinogenic action of
arsenic is not clear (1). As part of an interna-
tional effort to gather information and conduct
research along this line, the U.S. Armed Forces
Institute of Pathology (AFIP), with the support
of the U.S. Environmental Protection Agency,
the National Cancer Institute, and the
National Institute of Environmental Health
Sciences has developed the International Tissue
and Tumor Repository for Chronic Arsenosis
(ITTRCA) (6).
The diagnostic criteria for arsenic-
induced pathology has not been standardized
because of the large spectrum of lesions that
may be present in arsenic-exposed persons
and also because of the lack of an interna-
tional agreement on the criteria for diagnosis
of the lesions. The ITTRCA is striving to
obtain, archive, and make available for
research purposes, tissues from subjects
exposed to arsenic. Histopathologic material
submitted to the ITTRCA includes surgical
and autopsy specimens from patients exposed
to drugs or environmental substances. In
addition to tissues, clinical information for
each patient was furnished by the contribut-
ing facilities. The specimens were stained
with routine histochemical stains, usually
hematoxylin and eosin, with additional diag-
nostic studies such as immunohistochemistry
performed as needed.
ITTRCA hopes to contribute to an
understanding of chronic arseniasis, and
toward this end we are evaluating the
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pathology in a series of arsenic-exposed
cases. In addition to the two cases of liver
cancer, we briefly describe the most com-
mon arsenic-induced lesions found in skin,
based on three other case reports. All five
cases are from the ITTRCA, and the pathol-
ogy is considered highly probable to have
been induced by chronic arsenic exposure.
Presentation and Discussion 
of Cases
Arsenic-Induced Skin Lesions
Arsenic tends to concentrate in ectodermal
tissues, including the skin, hair, and nails,
even with low-level exposures. Thus, the skin
is a primary target organ for chronic arsenic
toxicity. Epidemiologic studies have conclu-
sively confirmed arsenic-induced cancers of
the skin. In nearly all cases where internal
cancers are attributed to arsenic exposure,
there has been cutaneous evidence of arsenic
exposure in the form of arsenical keratosis,
hyperpigmentation, and multiple cutaneous
malignancies (7). Arsenical keratosis is a well-
established clinical syndrome, characterized
by several specific pathological features,
including hyperkeratosis, parakeratosis,
arsenical pigmentation, and squamous cell
carcinoma in situ. Arsenical keratosis is most
pronounced on the feet and hands, although
it can occur on the trunk and other areas of
the extremities. In early stages of arsenical
keratosis, the presence of squamous cell carci-
noma in situ may not be evident. Bowen dis-
ease is squamous cell carcinoma in situ of the
skin, precancerous in nature, and sometimes
associated with arsenic exposure.
The most common arsenic-induced skin
cancers are squamous cell carcinomas and
basal cell carcinomas. Squamous cell carcino-
mas are true invasive carcinomas of the sur-
face epidermis, consisting of irregular masses
of epidermal cells that proliferate downward
and invade the dermis. Basal cell carcinomas
are tumors that arise from characteristic cells,
often referred to as basaloma cells. They have
a large, oval or elongated nucleus with rela-
tively little and poorly defined cytoplasm.
Histologically, tumors associated with arsenic
exposure do not differ from tumors unrelated
to arsenic. Designating arsenic as the
causative agent of these skin cancers fre-
quently relies on the location of these tumors
in sun-protected areas (because exposure to
the sun is the most common cause of skin
cancer) and the presence of other signs of
arsenic exposure (e.g., hyperkeratosis and
hyperpigmentation). We are presenting three
ITTRCA cases that demonstrate these
arsenic-induced skin lesions.
Case 1. A 76-year-old woman had a his-
tory of taking Fowler’s solution for psoriasis
for an unknown period of time. Fowler’s solu-
tion (1% potassium arsenite, an inorganic
arsenic solution) was used as a treatment for a
variety of medical disorders, including psoriasis
and syphilis. She presented with an ulcerated
lesion of the left breast that had been present
for a number of years. A biopsy was performed
and the pathology showed Bowen disease of
the breast (Figure 1). The lesion was inter-
preted as a squamous cell carcinoma in situ
consistent with Bowen disease. The entire
thickness of the epithelium showed dyskerato-
sis, disorientation of the cells, and acanthosis.
There was no histologic evidence of solar dam-
age in the examined material.
Case 2. In this case, a 47-year-old female
was treated with Fowler’s solution as a child
for persistent eczema. She developed squa-
mous cell carcinoma of the middle ﬁnger that
resulted in amputation at the metatarsal pha-
langeal joint. She apparently healed well, but
3 years later, keratosis developed at the suture
line. The squamous cell tumor consists of dis-
orderly foci of atypical squamous cells prolif-
erating into the dermis (Figure 2). The dermis
shows a moderate inﬂammatory reaction.
Case 3. A 37-year-old man was treated for
asthma for 2 years with a medication sus-
pected to contain arsenic. He developed mul-
tiple keratotic lesions of the right ﬁngers and
breast. In addition he developed basal cell
carcinoma of the neck (Figure 3). Arsenic is
one of the main causes of basal cell carcino-
mas in sun-protected areas, of which 90%
occur on the head and neck. A biopsy of the
basal cell carcinoma showed elongations of
the epidermis downward into the dermis with
nuclear palisading of the peripheral layer.
Arsenic-Induced Liver Lesions
Two types of liver cancer have been associated
with arsenic exposure: hepatocellular carci-
noma and angiosarcoma of the liver.
Hepatocellular carcinomas have been clearly
associated with ingested inorganic arsenic
since the early 1990s (8,9). Histologically,
hepatocellular carcinomas range from well dif-
ferentiated to quite anaplastic undifferentiated
lesions. In the moderately to well-differenti-
ated types, trabeculae are more than two or
three cells thick and are composed of tumor
cells that exhibit round to oval nuclei with a
high nuclear/cytoplasmic ratio and prominent
nucleoli. They are surrounded by sinusoidal
spaces. The malignant cells often have an
abundant eosinophilic cytoplasm and may
contain bile, fat, glycogen, or cytoplasmic
inclusions. In addition, other clues helpful in
diagnosis are the presence of mitoses, tumor
within vascular structures, and inﬁltration of
tumor into adjacent liver.
Angiosarcoma of the liver (hemangioen-
dothelial sarcoma) is a malignant neoplasm of
the liver constituting only 2% of all primary
liver tumors in Western countries. Researchers
have become more interested in this disease
because of its relationship with environmental
carcinogens such as vinyl chloride monomer,
thorium dioxide, and inorganic arsenic (10).
The relationship of chronic arsenic intoxica-
tion to angiosarcoma of the liver has been well
documented. Roth (11) described the correla-
tion between hepatic angiosarcoma and
arsenic-containing pesticide exposure in
German vineyard cultivators in the 1940s and
1950s. Regelson (12) was the ﬁrst to report a
similar case in the American literature. A
nationwide review of deaths from angiosar-
coma of the liver identiﬁed seven cases with a
history of prolonged use of Fowler’s solution,
which provided further support for the associ-
ation between chronic arsenic exposure and
angiosarcoma. Several reports in the literature
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Figure 1. Bowen disease. Atypical and pleomorphic
keratinocytes with scattered mitotic figures are
present at all levels of the hyperplastic epidermis.
Figure 2. Squamous cell carcinoma. Pleomorphic,
atypical keratinocytes extend into the dermis.
Figure 3. Basal cell carcinoma. Elongations of the
epidermis downward into the dermis with nuclear
palisading of the peripheral cell layer can be
observed (arrow).Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 885
have followed those seminal papers, one of
which documents a case of angiosarcoma and
hepatoportal sclerosis (HS; also known as
noncirrhotic portal hypertension) in the same
patient with chronic arsenic salt exposure
(13). The latent period in these studies varied
from 13 to 29 years.
Case 4. A 32-year-old white male was
treated with Fowler’s solution for dermatitis
herpetiformis. He used the medication daily
for 3 years, 10 years prior to admission to a
hospital for pain in the epigastric region. The
clinical record indicates that he developed
“arsenic poisoning.” Skin lesions characteris-
tic of arsenical keratosis were recorded at that
time. In addition his liver was noted to be
enlarged. There was no reported history of
alcohol use. Serologic studies were negative.
He died 2 months after admission, and an
autopsy attributed death to hepatic insuffi-
ciency. Examination of the liver at autopsy
revealed an enlarged liver (weight, 6,250 g)
with a large hemorrhagic and necrotic
nodule occupying two thirds of the liver.
Microscopic sections of liver showed necrosis
and a malignant epithelial-type tumor, diag-
nosed as hepatocellular carcinoma (Figure 4).
The tumor cells show considerable pleomor-
phism and eosinophilic cytoplasm. The
nuclei are irregular, hyperchromatic, and
occasionally multinucleated. Associated
cirrhosis can be observed.
Case 5. A 14-year-old boy lived in an area
of Argentina where the water was contami-
nated with arsenic. Since 5 years of age, he
had typical arsenic-induced lesions involving
the soles and palms. Initially, the lesions con-
sisted of hypochromatic macules that later
developed into hyperkeratotic lesions. The
boy was admitted to the hospital with symp-
toms suggestive of liver disease. Liver tests
performed at that time confirmed liver dis-
ease, which progressed rapidly with a fatal
outcome. Autopsy revealed an enlarged liver
with a large necrotic, hemorrhagic tumor in
the right lobe. Histologic examination
revealed malignant endothelial cells consistent
with the diagnosis of angiosarcoma of the
liver (Figure 5). Microscopically, there was
diffuse proliferation of atypical endothelial
cells infiltrating into existing sinusoidal
spaces. The diagnosis was confirmed with
immunohistochemical studies.
Hepatoportal Sclerosis
Hepatoportal sclerosis (also known as noncir-
rhotic portal ﬁbrosis, idiopathic portal hyper-
tension, and Banti syndrome) is a condition
characterized by portal hypertension without
evidence of liver cirrhosis. In HS there is no
evidence of extrahepatic portal vein obstruc-
tion or relation to congenital hepatic ﬁbrosis
or to any blood, parasitic, or granulomatous
diseases or other known diseases (14).
Clinically, HS is manifested by splenomegaly,
anemia, and episodes of gastrointestinal hem-
orrhage due to esophageal varices. HS is a
rare but relatively speciﬁc condition that may
occur after years of arsenic ingestion at con-
centrations of 0.01 mg/kg/day.
Histologically, HS is characterized by
thickening and sclerosis of the wall of large
portal vein branches. Increased perivascular
ﬁbrosis is seen in the portal tracts, which may
show obliteration or sclerosis of portal vein
branches. The portal vein lumen is reduced,
and organized thrombi with recanalization
may be seen. The bile ducts may show con-
centric periductal fibrosis. Lobular architec-
ture is maintained with some mild fibrous
bridging between the portal areas and the
portal and central areas.
Although the etiology of HS is usually
not known, chronic arsenic ingestion has
been associated with the development of the
disease in several different reports. Nevens
et al. (3) described eight patients with non-
cirrhotic portal hypertension who had been
treated for psoriasis and had received
Fowler’s solution some years previously.
Total arsenic intake was estimated to vary
from 4 to 16 g, with an interval between the
treatment and onset of symptoms of 2–16
years. These patients showed the character-
istic arsenical skin changes of keratosis and
melanosis, with malignant skin cancers pre-
sent in four of the patients. Datta et al. (15)
reported nine patients from northern India
with HS that had consumed high levels of
arsenic from contaminated drinking water,
adulterated opium, and indigenous medi-
cines. Typical signs of arseniasis were
observed along with high levels of arsenic in
the majority of the livers of these patients.
These reports support the hypothesis that
arsenic may cause HS by damage to the
intrahepatic portal veins.
Arsenic-Induced Cancers 
in Other Organs
The evidence for other arsenic-induced can-
cers has come from epidemiologic studies
because there are no suitable animal models to
conduct research on these issues. According to
a recent epidemiologic study of an area of
Taiwan with endemic blackfoot disease, high
mortality was found in males and females for
lung, bladder, kidney, and nasal cancers and
possibly cancers at other sites in addition to
those of the skin and liver. Generally speak-
ing, the outcomes of this study corroborate
the results of several other studies suggesting a
relationship between arsenic exposure and
cancers of the internal organs (16). For exam-
ple, arsenic has been implicated as a bladder
carcinogen in separate studies from Argentina,
Chile, and Taiwan (17). In addition, the
results of a recent study in Cordoba,
Argentina, add to the evidence that arsenic
ingestion increases the risk of kidney cancers
(18). An association between carcinoma of the
lung and inhaled arsenic is well established;
more recent studies have shown that ingested
arsenic may also be an etiologic factor in the
development of lung cancer (19).
Other Noncancer Effects of 
Chronic Arsenic Poisoning
As previously indicated, increased risks for a
variety of arsenic-induced noncancer effects
have been suggested. This includes peripheral
vascular disease, cardiovascular disease, diabetes
mellitus, neurologic effects, chronic lung dis-
eases, diminished hearing, and cerebrovascular
disease (1,2,20–24). It is quite apparent that
the hazardous effects of arsenic are multiorgan
related with extensive systemic pathology.
Although reproductive effects of arsenic in
humans have not been extensively investi-
gated, there is evidence from both animal and
human studies that suggests reproductive toxi-
city from arsenic. The human data are still
sparse, and the results from laboratory experi-
ments in animals are not conclusive. The few
human studies suggest that arsenic exposure
may increase the incidence of pre-eclampsia in
pregnant women, decrease birth weight of
newborn infants, and increase the risk of mal-
functions and stillbirths as well as spontaneous
abortions (25). Recent laboratory studies sug-
gest an increase in malformations and still-
births in animals (26,27); however, the effects
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Figure 4. Hepatocellular carcinoma. The nuclei are
irregular, hyperchromatic, and occasionally multi-
nucleated (e.g., arrow).
Figure 5. Angiosarcoma of the liver. Tumor cells
show marked pleomorphism and nuclear hyper-
chromasia (e.g., arrow).of arsenic from drinking water in human
reproduction have not been adequately stud-
ied (1). To assess the potential effects of
arsenic in human reproduction, a properly
designed epidemiologic study in a sufﬁciently
large population is necessary.
In conclusion, it is apparent that the health
effects of arsenic are systemic in nature and
may involve multiple organs. Epidemiologic
studies confirm the relationship between
chronic arsenic exposure and mortality from
various cancers, especially those of the skin,
lung, and bladder. We have presented in this
article two case reports that further implicate
arsenic as a causative agent in liver cancer. The
biological mechanisms by which arsenic exerts
its toxic and carcinogenic activities are not well
understood at this time. To completely assess
the potential adverse health risks of arsenic in
various exposure situations, it is important to
understand not only the mechanism(s) of
action but also metabolic and toxicokinetic
principles of arsenic activity. The search for
biomarkers of exposure continues to be equally
important as a means of identifying individuals
susceptible to carcinogenesis. Establishing clear
carcinogenic end points of arsenic exposure
remains the overriding goal in determining
intervention and preventing risks.
The cases presented here are from the
ITTRCA and include a range of pathologi-
cal conditions of the skin and liver that are
related to arsenic exposure. Conditions in
the skin include keratosis, hyperkeratosis,
parakeratosis, pigmentation (hypopigmenta-
tion, hyperpigmentation), squamous cell
carcinoma, and basal cell carcinoma. In
addition to fibrosis, liver pathology includes
hepatocellular carcinoma and angiosarcoma.
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